Global Leprosy Treatment Market Is Estimated To Witness High Growth Due To Growing Awareness And Rising Technological Advancements In Treatments And Diagnosis

 

Leprosy Treatment

Overview:

Leprosy is a disease caused by a bacterium called Mycobacterium Leprae. It can affect any person, it is most common in tropical areas of the world. It is usually spread through close, prolonged contact between people who have the infection. If left untreated, leprosy can cause permanent damage to the nerves in the body. That can lead to painful skin nodules, loss of sensation in hands and feet, and muscle paralysis. Antibiotics are used to kill the bacteria that cause leprosy. The drugs are usually taken for 6 months to a year, depending on the severity of the infection. Multidrug therapy (MDT) is the most common treatment for leprosy, and it’s been used successfully to treat more than 16 million people. More than 90% of people who start treatment with MDT will completely cure the disease.

Market Dynamics:

Growing prevalence of skin diseases is estimated to augment growth of the global Leprosy Treatment Market over the forecast period. For instance, 135 WHO Member States stated that in 2021, 140 546 new cases of leprosy were registered, and among this 55 346 individuals were females. Moreover, lack of medical facilities and awareness is anticipated to restrain growth of the global leprosy treatment market over the forecast period.

Impact of COVID-19:

 

The pandemic had a substantial impact on many countries around the world. Many countries had to impose strict lockdowns in order to prevent further transmission of the virus. The pandemic also had a huge impact on businesses and trade in various countries. Strict lockdowns resulted in shutting down of many industries and caused a shortage of raw materials globally. The global economy was also affected during the pandemic. The pandemic impacted the leprosy treatment in a negative manner. There was a shortage of skilled staff, community-based activities were banned and there was limited monitoring of nerve function impairment. This hampered the growth of the global leprosy treatment market during the pandemic.

 

Key Takeaways:

 

The global Leprosy Treatment Market is expected to witness high growth, exhibiting CAGR of 3.55 % over the forecast period, due to increasing initiatives by several organizations. For instance, the World Health Organization launched the Global Leprosy Strategy 2021–2030 “Towards zero leprosy” in April 2021. This strategy is aiming to scale up leprosy prevention, combat stigma, and manage its complications.

North America is anticipated to witness significant growth in the global Leprosy Treatment Market over the forecast period, owing to growing expenditure on healthcare and rising favorable reimbursements.

Major players operating in the global Leprosy Treatment Market are Lark Laboratories Ltd., Glaxo Smithcline, Astra Zeneca, Systopic Laboratories Pvt. Ltd., Novartis International AG, Cadila Pharmaceuticals, Macleods Pharmaceuticals, Pfizer Inc., Acme Pharmaceuticals, AstraZeneca plc, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Sanofi., Mylan N.V., and Perrigo Pharmaceutical plc.